IPO boom: Antibody experts at Genmab outline global ambition in pitch for $500M
Genmab has made a name — and some decent money — for itself as the heavyweight partner of J&J that came up with the blockbuster Darzalex (daratumumab). But for the Copenhagen-based biotech, it’s just the beginning of a journey to become an internationally acclaimed player in antibody-based cancer therapies.
The company laid out its vision in a filing for a whopping $500 million IPO late Tuesday, unequivocally stating that it plans to launch its own proprietary product — one it owns at least 50% of — by 2025. And there are at least five of these in the pipeline.
Basic subscription required
Unlock this story instantly and join 53,400+ biopharma pros reading Endpoints daily — and it's free.